指南与共识食管胃疾病与幽门螺杆菌消化内镜消化道肿瘤与早癌

AGA临床实践更新:胃息肉管理专家综述

AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2026-02-19

该专家综述由AGA临床实践更新委员会委托,针对胃黏膜息肉的诊断与管理提供指导。内容涵盖胃息肉的自然史、内镜检出与分类、内镜切除及术后监测,强调系统评估息肉及周围黏膜病理(如幽门螺杆菌胃炎、萎缩、肠化生)对制定管理策略的重要性。因未进行系统评价,最佳实践建议未对证据质量或推荐强度进行正式评级。

要点

  • 胃息肉包括多种组织学亚型,不同类型可共存,且与周围黏膜不同病理改变相关。
  • 腺瘤性或增生性胃息肉患者均应检测幽门螺杆菌,阳性者需治疗。
  • 因正当理由使用PPI者,若发现胃底腺增生相关息肉,无需停药。

核心结论

  • 胃息肉管理需综合息肉组织学类型及周围黏膜病理,系统评估后制定个体化切除与监测策略。

研究设计与样本

  • 由AGA临床实践更新委员会委托并批准的专家综述,基于文献回顾和专家意见形成最佳实践建议,未进行系统评价。

主要发现

  • 胃息肉包括胃底腺息肉、胃增生性息肉、错构瘤性息肉、胃腺瘤、幽门腺腺瘤、泌酸腺腺瘤和胃神经内分泌肿瘤等组织学亚型。
  • 不同组织学类型的胃息肉具有独特的地形特征、内镜特征和大小。
  • 不同类型胃息肉可共存于同一患者,且周围黏膜可呈现不同谱系的组织病理学异常。

关键数值与推荐

  • 腺瘤性或增生性胃息肉患者应检测幽门螺杆菌,阳性者应治疗。
  • 因正当理由使用PPI者,若存在胃底腺增生相关息肉,无需停药。
  • 低级别不典型增生息肉完全切除后1年随访监测,高级别不典型增生息肉完全切除后6个月随访监测。
  • 若息肉仅活检或切除不完全,高级别不典型增生建议3个月内随访内镜,低级别不典型增生建议6个月内随访。
  • 周围黏膜证实胃肠化生和/或萎缩性胃炎时,建议进行内镜监测。

临床怎么用

  • 内镜评估应包含高清白光和虚拟色素内镜等增强成像,并拍照记录息肉及周围黏膜异常。
  • 对息肉及周围黏膜进行系统活检,以评估幽门螺杆菌胃炎、自身免疫性胃炎、胃肠化生等基础病变。
  • 根据息肉组织学类型和周围黏膜病理制定监测计划,对多发息肉优先切除最大者并对小息肉取样或切除。

局限性

  • 未进行系统评价,最佳实践建议未对证据质量或推荐强度进行正式评级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: This Clinical Practice Update (CPU) expert review will advise clinicians on the diagnosis and management of gastric mucosal polyps. Gastric polyps are raised epithelial lesions of the gastric mucosa that can arise from various mucosal alterations and perturbations, including mucosal hyperplasia, adenoma, fundic gland proliferation, and enterochromaffin-like cell proliferation. Current guidance on the management of gastric polyps remains limited. This CPU provides a framework for understanding the natural history and epidemiology of gastric polyps and advises on best practices for the endoscopic detection and classification of gastric polyps, the endoscopic resection of gastric polyps, and endoscopic surveillance following resection. Because gastric polyps often occur within a field of altered gastric mucosa (eg, mucosal atrophy, pseudo-pyloric and intestinal metaplasia), we will advise on best practices for the sampling and surveillance of mucosal pathology giving rise to gastric polyps. This CPU is intended to complement other documents issued by the American Gastroenterological Association (AGA) Institute on gastric neoplastic and pre-neoplastic lesions, including the clinical practice guidelines on management of gastric intestinal metaplasia, as well as AGA CPUs on atrophic gastritis, high-quality upper endoscopy, and screening and surveillance of individuals at increased risk for gastric cancer. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these BPA statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE STATEMENTS BPA 1: Gastric polyps are frequently identified during upper endoscopy exams and include different histologic subtypes, such as fundic gland polyps (FGPs), gastric hyperplastic polyps (GHPs), hamartomatous polyps, gastric adenomas (GAs), pyloric gland adenomas, oxyntic gland adenomas, and gastric neuroendocrine tumors (G-NETs). BPA 2: Clinicians should be aware that different types of gastric polyps may coexist in the same person. BPA 3: Clinicians should be aware that different types of gastric polyps are associated with varying spectra of histopathologic abnormalities in the surrounding gastric mucosa, which may aid in their identification and diagnosis. BPA 4: Systematic endoscopic examination of the polyps and the surrounding gastric mucosa is essential in assessing the underlying gastric mucosa pathology (eg, Helicobacter pylori gastritis, autoimmune gastritis, gastric intestinal metaplasia [GIM]) and determining subsequent management: biopsies of the polyps, biopsies of the surrounding mucosa, and resection of the polyps. BPA 5: All patients with adenomatous or hyperplastic gastric polyps should be tested and treated if positive for H pylori infection. BPA 6: Patients who are using proton pump inhibitors (PPIs) for valid reasons do not need to discontinue these medications in the presence of documented fundic gland hyperplasia-related gastric polyps. BPA 7: Clinicians should be aware that different histological types of gastric polyps have unique/characteristic topographical features, endoscopic features, and size. BPA 8: Endoscopic evaluation of patients with gastric polyps should include complete inspection with high-definition white-light and enhanced imaging, such as virtual chromoendoscopy. Endoscopists should recognize and photo-document the endoscopic features of gastric polyps as well as the surrounding gastric mucosal abnormalities. BPA 9: Clinicians should be aware that endoscopic resection of the polyps includes traditional techniques (snare and biopsy forceps, mucosal resection) or endoscopic submucosal dissection. BPA 10: In the presence of numerous gastric polyps of varied sizes, the largest polyps should be resected when possible, and the smaller polyps sampled or resected. BPA 11: Suspected abnormalities in the surrounding mucosa, such as GIM or atrophic gastritis, should undergo targeted biopsies according to the existing protocols. BPA 12: Surveillance plans in patients with gastric polyps should be formulated based on the histopathological type of the polyps and the surrounding gastric mucosa. BPA 13: When a dysplastic lesion in the polyp is confirmed and resected completely, a follow-up surveillance endoscopy should be completed in 1 year for patients with low-grade dysplasia polyps and 6 months for patients with high-grade dysplasia polyps. If the polyp is biopsied or resection is incomplete, follow-up endoscopy is advised within 3 months for high-grade dysplasia and 6 months for low-grade dysplasia. BPA 14: Endoscopic surveillance is advised in patients with gastric polyps when the histopathology of adjacent mucosa confirms GIM and/or atrophic gastritis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Buchner AM, Huang RJ, Lauwers GY, et al. AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 41711625. doi:10.1016/j.cgh.2026.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。